Janux Therapeutics, Inc.
JANX
$16.12
$0.120.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5,366.97% | 47.10% | -5.55% | -23.37% | -97.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5,366.97% | 47.10% | -5.55% | -23.37% | -97.10% |
| Cost of Revenue | 25.06% | 60.83% | 84.09% | 92.49% | 86.70% |
| Gross Profit | -1.30% | -62.66% | -100.51% | -124.81% | -159.91% |
| SG&A Expenses | -5.65% | -1.11% | 1.76% | -0.14% | 65.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.30% | 38.88% | 53.21% | 55.83% | 79.27% |
| Operating Income | 0.91% | -38.21% | -59.51% | -67.85% | -119.74% |
| Income Before Tax | 2.89% | -47.25% | -64.69% | -68.32% | -139.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.89% | -47.25% | -64.69% | -68.32% | -139.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.89% | -47.25% | -64.69% | -68.32% | -139.85% |
| EBIT | 0.91% | -38.21% | -59.51% | -67.85% | -119.74% |
| EBITDA | 0.80% | -38.97% | -60.80% | -69.54% | -123.60% |
| EPS Basic | 8.50% | -35.52% | -43.29% | -42.46% | -96.30% |
| Normalized Basic EPS | 8.50% | -35.50% | -43.27% | -42.45% | -96.28% |
| EPS Diluted | 8.50% | -35.52% | -43.29% | -42.46% | -96.30% |
| Normalized Diluted EPS | 8.50% | -35.50% | -43.27% | -42.45% | -96.28% |
| Average Basic Shares Outstanding | 6.22% | 9.24% | 15.31% | 18.42% | 20.04% |
| Average Diluted Shares Outstanding | 6.22% | 9.24% | 15.31% | 18.42% | 20.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |